UCLB and Cycle Pharmaceuticals enter into partnership to repurpose drugs for liver diseases

UCLB is pleased to announce that it has entered into a partnership agreement with Cycle Pharmaceuticals to develop existing drugs for new uses in treating liver diseases. UCLB has licensed Intellectual Property from research carried out at UCL (University College London) to Cycle Pharmaceuticals as a part of this transaction.

Dr Jude Oben, Consultant Hepatologist & Senior Lecturer in Hepatology, commented: “Liver diseases touch a majority of us either directly, or through us caring for someone suffering from these diseases. My research and clinical goals have always been to help liver disease patients through new treatment development. I believe that existing drugs, currently approved for other purposes, have a central role to play in tackling liver diseases, and I look forward to the partnership with Cycle Pharmaceuticals proving this – for the benefit of patients.”

James Harrison, CEO of Cycle Pharmaceuticals, added: “Improving existing drug treatments is all that we do. This includes repurposing of existing drugs for new uses. We are excited by such opportunities to help liver disease patients and we look forward to continuing to work with UCL and their exceptional academic and clinical teams.”

Dr Bill Lindsay, Senior Business Manager at UCLB commented, “UCLB is pleased to be collaborating with Cycle Pharmaceuticals to repurpose existing drugs for new uses in treating liver diseases. UCLB is committed to bringing new treatments developed by UCL researchers to patients.”

About UCLB
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.

For further information, please visit: www.uclb.com